



(51) International Patent Classification:

C07D 403/12 (2006.01) C07D 409/14 (2006.01)
 C07D 231/38 (2006.01) C07D 417/12 (2006.01)
 C07D 401/12 (2006.01) A61K 31/36 (2006.01)
 C07D 405/12 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/US2013/031464

(22) International Filing Date:

14 March 2013 (14.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/612,007 16 March 2012 (16.03.2012) US

(71) Applicant: **AXIKIN PHARMACEUTICALS, INC.**
 [US/US]; 10835 Road To The Cure, Suite 250, San Diego,
 CA 92121 (US).

(72) Inventors: **RAAUM, Erik, Dean**; 10835 Road To The
 Cure, Suite 200, San Diego, CA 92121 (US). **POTTER,
 Garrett, Thomas**; 10835 Road To The Cure, Suite 250,
 San Diego, CA 92121 (US). **LY, Tai, Wei**; 10824 Cam-
 inito Colorado, San Diego, CA 92131 (US).

(74) Agents: **GEORGE, Nikolaos, C.** et al.; Jones Day, 222
 East 41st Street, New York, NY 10017-6702 (US).


(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
 NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
 ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS



(IA)

(57) Abstract: Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.